摘要
The field of circulating tumor cell(CTC)enrichment has seen many emerging technologies in recent years,which have resulted in the identification and monitoring of clinically relevant,CTC-based biomarkers that can be analyzed routinely without invasive procedures.Several molecular platforms have been used to investigate the molecular profile of the disease,from high throughput gene expression analyses down to single cell biological dissection.The established presence of CTC heterogeneity nevertheless constitutes a challenge for cell isolation as the several subpopulations can potentially display different molecular characteristics;in this scenario,careful consideration must be given to the isolation approach,whereas methods that discriminate against certain subpopulations may result in the exclusion of CTCs that carry biological relevance.In the context of prostate cancer,CTC molecular interrogation can enable longitudinal monitoring of key biological features during treatment with substantial clinical impact,as several biomarkers could predict tumor response to AR signaling inhibitors(abiraterone,enzalutamide)or standard chemotherapy(taxanes).Thus,CTCs represent a valuable opportunity to personalize medicine in current clinical practice.
基金
supported by the Clinical and Translational Science Center at Weill Cornell NIH/NCATS grant ULTR00457(to GG)
the NIH T32 Training grant 5T32CA062948-22(to GG)
by the National Institutes of Health(NIH)Grants R01 CA137020(to PG)and R01 CA179100(to PG).
